Dr. Pilar González Cabo

Principal Investigator
Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases – NeuroFisER

Dr. González-Cabo has a degree in Biological Sciences, with specialty in Biochemistry, from the University of Valencia. Throughout her research career, she has developed her research in different fields, but always in the environment of rare diseases.

She obtained her PhD at the Institute of Biomedicine of Valencia (IBV, CSIC) in the field of genetics and comparative functional genomics of cerebellar ataxias under the direction of Dr. Palau. As a postdoc, at the same IBV and later at the Príncipe Felipe Research Center, she successfully initiated a new line of research to study the role of mitochondria in human disease and neurodegeneration. During this time, she made stays in prestigious centers such as the University of Cambridge or Cancer Research UK.

Since 2007 she has been a researcher at the CIBER of Rare Diseases, and from 2016 she joined as an associate researcher at INCLIVA, as part of the Cellular and Organic Pathophysiology of Oxidative Stress Research Group led by Dr. Federico Pallardó. In the last 11 years she has obtained, uninterruptedly, her own funding as Principal Investigator. Research grants are included in different state and regional competitive programs, both public and private, as well as service contracts with private companies.

She is currently an associate professor in the Department of Physiology of the Faculty of Medicine and Dentistry of the University of Valencia.

Dr. Pilar González Cabo


Therapeutic strategies targeting mitochondrial calcium signaling: a new hope for neurological diseases?. Rodríguez LR, Lapeña-Luzón T, Benetó N, Beltran-Beltran V, Pallardó FV, Gonzalez-Cabo P, Navarro JA. Antioxidants. 2022 Jan 15;11(1):165. doi: 10.3390/antiox11010165. PMID: 35052668

Antioxidant Therapies and Oxidative Stress in Friedreichs Ataxia: The Right Path or Just a Diversion?. Rodriguez Melguizo L, Lapeña Luzón T, Calap Quintana P, Moltó Ruiz M, González Cabo P, Navarro Langa J. Antioxidants (Basel, Switzerland). 2020 Jul 24;9(8):664. doi: 10.3390/antiox9080664. PMID: 32722309

Cofilin dysregulation alters actin turnover in frataxin-deficient neurons. Muñoz Lasso D, Molla B, Calap Quintana P, Garcia Gimenez J, Pallardo Calatayud F, Palau F, González Cabo P. Scientific Reports. 2020 Mar 23;10(1):5207. doi: 10.1038/s41598-020-62050-7. PMID: 32251310

Oxidative stress modulates rearrangement of endoplasmic reticulum-mitochondria contacts and calcium dysregulation in a Friedreich’s ataxia model. Rodríguez LR, Calap-Quintana P, Lapeña-Luzón T, Pallardó FV, Schneuwly S, Navarro JA, Gonzalez-Cabo P. Redox Biology. 2020 Oct 16;37:101762. doi: 10.1016/j.redox.2020.101762. PMID: 33128998

Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich’s Ataxia. Seco-Cervera M, Gonzalez-Cabo P, Pallardo F, Roma-Mateo C, Garcia-Gimenez J. Antioxidants. 2020 Dec 10;9(12):E1257. doi: 10.3390/antiox9121257. PMID: 33321938

Referencia: ACCI 2020
Título: Síndrome de CANVAS: diagnóstico precoz y modelo fisiopatológico mediante iPSC.
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Pilar González Cabo
Duración: 2021 – 2022
Presupuesto: 75.000 €

Referencia: PID2020-115190RB-I00
Título: Relacionando cofilina, una proteína de unión a actina, con la desregulación del calcio: un enfoque de precisión para el tratamiento de la ataxia de Friedreich
Entidad Financiadora: Ministerio de Ciencia e Innovación
Investigador principal: Pilar González Cabo
Duración: 2021 – 2023
Presupuesto: 196.300 €

Referencia: ACCI-2019-22
Título: Degradación de la huntingtina mediante ubiquibodies de camélidos
Entidad Financiadora: CIBER de Enfermedades Raras (CIBERER-ISCIII)
Investigador principal: Pilar González Cabo
Duración: 2020 – 2022
Presupuesto: 18.000 €

Referencia: RTC2019-006825-1
Título: Potencial de la leriglitazona para el tratamiento de enfermedades asociadas a la acumulación de hierro, distrofias y enfermedades neuromusculares
Entidad Financiadora: Ministerio de Ciencia e Innovación
Investigador principal: Pilar González Cabo
Duración: 2020 – 2023
Presupuesto: 90.000 €

Referencia: ACCI-CIBERER 2018
Título: Edición Génica del Gen FXN mediante el Sistema CRISPR/Cas9 en linfocitos de pacientes con ataxia de Friedreich
Entidad Financiadora: CIBER de Enfermedades Raras (CIBERER-ISCIII)
Investigador principal: Pilar González Cabo
Duración: 2019 – 2021
Presupuesto: 39.750 €